MGMT and neoplasm: In this study, we characterized methylation of single CpG sites of the MGMT promoter in tumor samples from first neurosurgical intervention in a cohort of 69 glioblastoma multiforme (WHO grade IV) and 11 anaplastic astrocytoma (WHO grade III) patients, who subsequently received radiotherapy and temozolomide treatment.